Charles Schwab Trust’s Biogen BIIB Stock Holding History

Charles Schwab Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$670K	Buy	+3,101	New	+$593K	0.04%	117

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charles Schwab Trust's BIIB Position: Q2 2026 in Review

Charles Schwab Trust opened a new position in Biogen (BIIB) in Q2 2026: 3,101 shares worth $670K. The stake represents 0.04% of the portfolio and ranks #117 among its holdings.

1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Charles Schwab Trust held 3,101 shares of Biogen worth $670K as of Q2 2026.
Biogen was a new Charles Schwab Trust position in Q2 2026.
Biogen made up 0.04% of Charles Schwab Trust's portfolio in Q2 2026, its #117 holding.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Charles Schwab Trust's 13F filing for Q2 2026, filed 10 Jul 2026.